On the average, humans – and pigs, and deer, and birds – who live at high altitudes have better blood glucose control than their counterparts near sea level. In work published in the Feb. 19, 2026, issue of Cell Metabolism, investigators have linked this phenomenon to red blood cells that directly take up and metabolize glucose from the blood under low oxygen conditions. Read More
At a time of global transition for life sciences, with China stepping up the pace of innovation and the U.S. adopting protectionist policies, the health innovation region in Catalonia, Spain, is emerging as one of the most dynamic hubs in Europe. Last year, the region, centered on Barcelona, saw growth of 8.3% over 2024, and there are now 1,650 companies, including 423 biotechs, 259 digital health specialists and 238 med techs. Read More
Animate Biosciences Inc.’s lead therapeutic peptide MBb32 produced a significant reduction in cardiac scar tissue and subsequent recovery of heart function in a mouse model of severe myocardial injury. Read More
Lario Therapeutics Ltd. has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform. The funding provides validation of Lario’s work on selective small-molecule inhibitors of voltage-gated neuronal calcium channels. Read More
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Read More
At the ongoing AACR Immuno-Oncology Conference (AACR IO) in Los Angeles, Ampersand Biomedicines Inc. gave a presentation on promising results in the field regarding AMP-410, an anti-VEGF/4-1BB antibody construct that limits 4-1BB activation in VEGF-rich tumor types, thus achieving durable efficacy. Read More
Chong Kun Dang Pharmaceutical Corp. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders. Read More
Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation. Read More
Researchers from Shandong First Medical University (China) and collaborators have published a comprehensive study on the screening, synthesis, structure-activity relationship and biological evaluation of 1,2,4-oxadiazole derivatives that selectively inhibit SPHK2. Read More
Hangzhou Innogate Pharma Co. Ltd. has reported cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors. They are described as useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, myocardial infarction and Parkinson’s disease, among others. Read More
The potential of G9A as a therapeutic target was investigated in vitro in vascular smooth muscle cells as well as in vivo in a murine model of vascular intimal hyperplasia. Read More
Beijing Konruns Pharmaceutical Co. Ltd. has patented new transforming acidic coiled-coil-containing protein (TACC) inhibitors described as potentially useful for the treatment of cancer. Read More
Chugai Pharmaceutical has reported a new humanized antibody (Ab, SOF-10) that targets latent TGF-β1 and selectively blocks protease- and integrin αVβ8-mediated latent TGF-β1 activation. Read More
